Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: Contribution of diagnostic laparoscopy

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Brun, Jean Luc ^a   Rouzier, Roman ^a,b   Selle, Frédéric ^a   Houry, Sidney ^a   Uzan, Serge ^a,b   Daraï, Emile ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; CLINICAL COMPETENCE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LAPAROSCOPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT SELECTION; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SURGEON; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; FEASIBILITY STUDY; METHODOLOGY; MIDDLE AGED; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEASIBILITY STUDIES; FEMALE; HUMANS; LAPAROSCOPY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649873300     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-171     Document Type: Article

References (27)

1. Griffiths CT Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 1975, 42:101-4 1234624
2. Chi DS Liao JB Leon LF Venkatraman ES Hensley ML Bhaskaran D Hoskins WJ Identification of prognostic factors in advanced epithelial ovarian carcinoma Gynecol Oncol 2001, 82:532-7 10.1006/gyno.2001.6328 11520151
3. Baekelandt M The potential role of neoadjuvant chemotherapy in advanced ovarian cancer Int J Gynecol Cancer 2003, 13:163-8 10.1111/ j.1525-1438.2003.13354.x 14656274
4. Huober J Meyer A Wagner U Wallweiner D The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer J Cancer Res Clin Oncol 2002, 128:153-60 10.1007/s00432-001-0312-3 11935302
5. Bristow RE Eisenhauer EL Santillan A Chi DS Delaying the primary surgical effort for advances ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 2007, 104:480-90 10.1016/j.ygyno.2006.11.002 17166564
6. Martinez-Said H Rincon DG Montes De Oca MM Ruiz GC Ponce JLA Lopez-Graniel CM Predictive factors for irresectability in advanced ovarian cancer Int J Gynecol Cancer 2004, 14:423-30 10.1111/ j.1048-891x.2004.014301.x 15228414
7. Bristow RE Duska L Lambrou N Fishman EK O'Neill MJ Trimble EL Montz FJ A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer 2000, 89:1532-40 10.1002/ 1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A 11013368
8. Dowdy S Mullany S Brandt K Huppert B Cliby W The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 2004, 101:346-52 10.1002/ cncr.20376 15241833
9. Clough KB Ladonne JM Nos C Renolleau C Validire P Durand JC Second look for ovarian cancer: Laparoscopy or laparotomy? A prospective comparative study Gynecol Oncol 1999, 72:411-7 10.1006/gyno.1998.5272 10053115
10. Vergote I De Wever I Tjalma W Van Gramberen M Decloedt J van Dam P Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients Gynecol Oncol 1998, 71:431-6 10.1006/gyno.1998.5213 9887245
11. Fagotti A Fanfani F Ludovisi M Lo Voi R Bifulco G Testa AC Scambia G Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: A pilot study Gynecol Oncol 2005, 96:729-35 10.1016/j.ygyno.2004.11.031 15721418
12. Angioli R Palaia I Zullo MA Muzii L Manci N Calcagno M Benedetti Panici P Diagnostic open laparoscopy in the management of advanced ovarian cancer Gynecol Oncol 2006, 100:45-61 10.1016/j.ygyno.2005.09.060
13. Deffieux X Castaigne D Pomel C Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer Int J Gynecol Cancer 2006, 16(Suppl 1):35-40 10.1111/ j.1525-1438.2006.00323.x 16515565
14. Bristow RE Tomacruz RS Armstrong DK Trimble EL Monz FJ Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during platinum era: A meta-analysis J Clin Oncol 2002, 20:1248-59 10.1200/ JCO.20.5.1248 11870167
15. Fagotti A Ferrandina G Fanfani F Ercoli A Lorusso D Rossi M Scambia G A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study Ann Surg Oncol 2006, 13:1156-61 10.1245/ASO.2006.08.021 16791447
16. Unzelman RF Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital Am J Obstet Gynecol 1992, 166:1663-71 1615973
17. Junor EJ Hole DJ Gillis CR Management of ovarian cancer: Referral to a multidisciplinary team matters Br J Cancer 1994, 70:363-70 8054286
18. Eisenkop SM Spirtos NM Montag TW Nalick RH Wang HJ The impact of subspecialty training on the management of advanced ovarian cancer Gynecol Oncol 1992, 47:203-9 10.1016/0090-8258(92)90107-T 1468698
19. Michel G DeIaco P Castaigne D el-Hassan MJ Lobreglio R Lhomme C Rey A Duvillard P Extensive cytoreductive surgery in advanced ovarian carcinoma Eur J Gynaecol Oncol 1997, 18:9-15 9061314
20. Winter WE Maxwell GL Tian C Carlson JW Ozols RF Rose PG Markman M Armstrong DK Muggia F McGuire WP Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J Clin Oncol 2007, 25:3621-27 10.1200/JCO.2006.10.2517 17704411
21. Tannock I Cell kinetics and chemotherapy: A critical review Cancer Treat Rep 1979, 62:1117-33
22. Golde JH Coldman AJ A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate Cancer Treat Rep 1979, 63:1727-33 526911
23. Kuhn W Rutke S Spathe K Schmalfeldt B Florack G vonHundelshauen B Pachyn D Ulm K Graeff H Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma Cancer 2001, 92:2581-91 10.1002/ 1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#
24. Dowdy S Mullany S Brandt K Huppert B Cliby W The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 2004, 101:346-52 10.1002/ cncr.20376 15241833
25. Inciura A Simavicius A Juozaityte E Kurtinaitis J Nadisauskiene R Svedas E Kajenas S Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: A retrospective study of 574 patients BMC Cancer 2006, 6:153 1533845 16759398 10.1186/1471-2407-6-153
26. Morice P Dubernard G Rey A Atallah D Pautier P Pomel C Lhommé C Duvillard P Castaigne D Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer J Am Coll Surg 2003, 197:955-63 10.1016/j.jamcollsurg.2003.06.004 14644284
27. Chan YM Ng TY Ngan HYS Wong LC Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study Gynecol Oncol 2003, 88:9-16 10.1006/gyno.2002.6849 12504620